Pfizer Lifts Full-Year Outlook After Q3 Earnings Beat on Eliquis Strength
Pfizer (PFE) raised its 2023 profit and revenue forecasts after Q3 earnings beat estimates, driven by strong sales of Eliquis and Padcev. Adjusted EPS was $0.87 vs. $0.73 expected, and revenue was $16.58B vs. $15.87B expected. Full-year guidance increased to $2.95-$3.05 EPS and $62B-$64B revenue.
How this was made
The 30-second read
Why it matters
The guidance lift is a fresh, primary disclosure that can shift valuation multiples and investor sentiment.
Market read
First‑report earnings and guidance lift for a large‑cap pharma, likely to move the stock and sector.
What to watch
Potential patent expirations on older blockbusters and regulatory risks for new drugs could temper upside.
Background
Pfizer reported Q3 results, beating estimates and announced higher full‑year guidance for earnings and revenue.
Ticker impact
Pfizer raised its full-year EPS and revenue guidance after beating Q3 earnings expectations.
upside pressure as investors price in higher earnings and revenue forecasts
The new EPS range $2.95‑$3.05 and revenue $62‑$64B exceed prior guidance and beat consensus, a material catalyst for a large‑cap pharma.
Market effects
Raises expectations for the broader pharma sector as non‑COVID growth gains traction.
U.S. large‑cap equities may see modest uplift from the surprise guidance lift.
May influence global healthcare indices and foreign investors tracking U.S. pharma earnings.
Counterpoint
If cost‑cutting fails or Eliquis faces pricing pressure, the guidance could be overly optimistic.
Key entities
- companyPfizer
U.S. pharmaceutical giant reporting earnings and guidance.
